

## Table of contents

<b>Introduction .....</b>	<b>1</b>
1.1. Breast cancer.....	3
1.1.1. Epidemiology.....	3
1.1.2. Risk factors .....	4
1.1.3. Screening and diagnosis .....	6
1.1.4. Classification and staging.....	7
1.1.4.1. Histological and anatomical classification .....	7
1.1.4.2. Pathological classification.....	10
1.1.4.3. Molecular classification.....	11
1.1.5. Treatment.....	13
1.2. Tumor microenvironment .....	17
1.2.1. Cancer-associated fibroblasts .....	21
1.2.1.1. Origin and heterogeneity .....	21
1.2.1.2. Implications in tumor microenvironment.....	26
1.2.1.3. Implications in tumor progression and therapy resistance .....	29
1.3. Nanoparticles in medicine .....	36
1.3.1. Mesoporous silica nanoparticles.....	41
1.3.2. Modulation and targeting of tumor microenvironment by nanoparticles.....	45
1.3.2.1. Nanoparticles targeting cancer-associated fibroblasts ... .....	54

TABLE OF CONTENTS

<b>Objectives.....</b>	<b>57</b>
<b>Materials and Methods .....</b>	<b>61</b>
3.1. Cell culture .....	63
3.1.1. Commercial cell lines .....	63
3.1.2. Cancer-associated fibroblasts .....	63
3.1.3. Patient-derived organoids .....	65
3.2. Gene expression studies .....	67
3.3. Western blot .....	68
3.4. Nanoparticles' synthesis .....	69
3.5. Nanoparticles' characterization .....	70
3.6. Control release studies .....	71
3.7. Hemolysis assay.....	72
3.8. Cellular uptake and targeting efficacy .....	73
3.8.1. 2D culture models .....	73
3.8.2. 3D culture models .....	73
3.9. Cellular cytotoxicity.....	74
3.9.1. 2D culture models .....	74
3.9.2. 3D culture models .....	75
3.10. <i>In vivo</i> studies.....	76
3.10.1. <i>In vivo</i> model.....	76
3.10.2. Doxorubicin penetration .....	77
3.10.3. Masson's trichrome staining.....	77
3.10.4. Immunofluorescence.....	78

## TABLE OF CONTENTS

3.10.5. Flow cytometry .....	78
3.11. Statistical analysis.....	80
<b>Results .....</b>	<b>81</b>
4.1. Synthesis and characterization of nanoparticles targeting cancer-associated fibroblasts.....	83
4.2. FAP- $\alpha$ expression in breast cancer cells, cancer-associated fibroblasts, and patient-derived organoids.....	91
4.3. Nanoparticles' targeting efficacy in breast cancer cells, cancer-associated fibroblasts, and patient-derived organoids.....	94
4.4. Nanoparticles' cytotoxic efficacy in breast cancer cells, cancer-associated fibroblasts, and patient-derived organoids.....	100
4.5. Nanoparticles' <i>in vivo</i> antitumoral efficacy in a triple-negative breast cancer mouse model.....	102
4.6. Nanoparticles' <i>in vivo</i> targeting of cancer-associated fibroblasts .....	106
4.7. Nanoparticles' <i>in vivo</i> tumor microenvironment modulation .	107
4.8. Nanoparticles' <i>in vivo</i> biocompatibility and safety.....	110
<b>Discussion .....</b>	<b>115</b>
<b>Conclusions.....</b>	<b>123</b>
<b>Bibliography .....</b>	<b>127</b>
<b>Appendix.....</b>	<b>175</b>